Financial Performance - Eversource Energy reported Q2 2025 EPS of $0.96, slightly better than the prior year[22] - The company reaffirms its 2025 EPS guidance of $4.67 - $4.82 and a long-term EPS growth rate of 5% - 7% through 2029[23] - The company's FFO to Debt ratio as of March 31, 2025, was 13.7%, exceeding the Moody's downgrade threshold of 9% and S&P's threshold of 12%[50] Capital Investments and Regulatory Updates - Eversource plans a capital investment of $24.2 billion through 2029, with 60% of distribution capital investment in Massachusetts[18] - The company anticipates incremental investments of $1.5 billion - $2 billion during this forecast period[47] - A permanent rate increase of $100 million was received in New Hampshire, effective August 1, 2025, as part of the PSNH rate case[39] - Massachusetts will see an EGMA Rate Base Reset with a November 2024 rate increase of $77 million and a November 2025 rate increase of $62 million[45] Strategic Priorities - Eversource is focused on being a 100% regulated utility, investing in line with state policies while maintaining customer reliability and affordability[18] - The company aims to strengthen its balance sheet and enhance its FFO to Debt ratio[18] - Eversource is leading the energy transition in New England with approximately $2 billion in T&D energy investments through 2029[18] Balance Sheet and Credit Metrics - Eversource has an At-The-Market (ATM) program for $1.2 billion of equity, issuing 3.4 million shares through June 2025 with net proceeds of $218 million[51, 60]

North America's Leading Copper Developer Permitted, In Construction, Scalable & Unmatched Corporate Presentation August 2025 TSX: FOM | US OTC: FMCXF | FORANMINING.COM TSX: FOM | US OTC: FMCXF | FORANMINING.COM Forward Looking Statements This presentation contains certain forward-looking information and forward-looking statements, as defined under applicable securities laws (collectively referred to herein as "forward-looking statements"). These statements relate to future events or to the future performanc ...

Financial Performance - Net sales increased by 1.0%[22] - Organic sales increased by 1.8%, including a 0.6% negative impact from lower private label pet sales[22] - Base Business EPS increased by 1%[22] Guidance - Net sales growth is still expected to be up low single digits, now including a flat to low-single-digit negative impact from foreign exchange[29] - Organic sales growth is now expected to be at the low end of 2% to 4%, including the impact over the course of 2025 of the planned exit from private label pet sales[32] - GAAP EPS is still expected to be up low single digits[29] - Base Business EPS is still expected to be up low single digits[32] Productivity Program - A new three-year productivity program is projected to result in cumulative pre-tax charges totaling between $200 and $300 million[26] Raw Material Costs - The company's current expectation for incremental tariff impact is approximately $75 million[36] Market Share - Global toothpaste market share was up 20 basis points on a volume basis year to date[22] Company Overview - Colgate-Palmolive is a $20.1B global consumer products company[7]

Financial Performance & Market Position - Cinemark reported second quarter total revenue of $941 million, a 28% increase year-over-year[35] - The company generated the highest quarterly Adjusted EBITDA and Adjusted EBITDA margin post-pandemic with $232 million and 24.7%, respectively[35] - Cinemark's domestic box office recovery surpassed the North American industry by over 1,000 basis points[35] - The company maintained core structural market share growth vs FY19 in excess of 100 bps in the U S and Latin America[35] - For the first half of 2025, Cinemark reported ~$1 5 billion of total revenue, an increase of 13% year-over-year[37] - Adjusted EBITDA for 1H25 was $269 million, representing an increase of 26% year-over-year, with an Adjusted EBITDA margin expansion of 190 bps to 18 1%[37] Assets & Customer Loyalty - Cinemark has consistently allocated $80-$100 million for global maintenance capex to maintain a high-quality circuit[15] - Approximately 70% of the U S footprint features reclined luxury seats[15] - Movie Club members increased to 1 45 million, growing 12% year-over-year and over 50% vs 2019, representing nearly 30% of domestic 2Q25 box office[35] Capital Allocation & Debt Management - The company is committed to repaying the $460 million principal amount of convertible notes maturing August 15, 2025, using cash on hand[48] - Cinemark repurchased $200 million of stock in March 2025 to proactively mitigate potential dilution from warrants, reducing share count by 7 93 million[48]

Second Quarter 2025 Earnings Presentation August 1, 2025 1 Forward-Looking Statements; Non-GAAP Financial Information Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect our current views with respect to, among other things, our operations and financial performance. Forward-looking statements include all statements that are not historical facts. These forward-lo ...

Financial Performance - Net sales decreased by 99% from $4383 million to $3948 million in Q2 2025[37] - Comparable sales decreased by 105%[37] - Adjusted earnings per share decreased by 243% from $037 to $028[37] - Adjusted free cash flow was an outflow of $24 million year-to-date[60] Segment Performance - ACCO Brands Americas sales decreased by 150% from $2923 million to $2485 million[42] - ACCO Brands International sales increased slightly by 02% from $1460 million to $1463 million[42] - ACCO Brands Americas adjusted operating income decreased by 316% from $632 million to $432 million[42] - ACCO Brands International adjusted operating income increased by 60% from $117 million to $124 million[42] Cost Reduction and Debt - The company is executing a multi-year cost reduction program targeting at least $100 million in savings[32] - Over $40 million in savings have been realized since the program's inception[35] - Net debt decreased by $19 million year-over-year[16] Outlook - Q3 2025 net sales are projected to be between $387 million and $400 million, a decrease of 50% to 80%[63] - Full year 2025 net sales are projected to be between $1525 billion and $1550 billion, a decrease of 70% to 85%[67]

Financial Performance - Regeneron reported total revenues of $3.68 billion for Q2 2025[8] - Non-GAAP EPS for Q2 2025 was $12.89[8] - Dupixent global net sales reached $4.3 billion in Q2 2025, representing a 21% year-over-year increase[9] - EYLEA HD and EYLEA together held approximately 61% of the U S branded anti-VEGF category share in Q2 2025[22] - Libtayo global net sales for Q2 2025 were $377 million, a 25% year-over-year increase[30] Dupixent Expansion - Dupixent is approved for eight indications globally and has reached approximately 12 million patients worldwide[9] - The U S FDA approved Dupixent for chronic spontaneous urticaria (CSU) in April 2025 and bullous pemphigoid (BP) in June 2025[9, 19] - Dupixent was approved by the FDA in late September 2024 for COPD[11] Pipeline Developments - Lynozyfic received approval in the U S and Europe for relapsed/refractory multiple myeloma and was added to NCCN treatment guidelines[8] - The company initiated the first Phase 3 study for Factor XI (REGN7508) in VTE prevention after total knee replacement surgery[8] - Regeneron in-licensed olatorepatide/HS-20094 (dual GLP-1/GIP receptor agonist) to evaluate as a monotherapy and study combinations to address muscle loss and other comorbidities of obesity[8] Reimbursement and Development Balance - Reimbursement of Sanofi's antibody development balance is expected to average approximately $800 million per year in 2025 and 2026[15] - As of June 30, 2025, the antibody development balance stood at approximately $1.2 billion[17]

Q2 2025 RESULTS AUGUST 1, 2025 © 2025 Fluor Corporation. All Rights Reserved. Fluor is a registered service mark of Fluor Corporation. 1 LNG CANADA EXPORT FACILITY // KITIMAT, B.C., CANADA SAFE HARBOR STATEMENT This presentation contains forward-looking statements (including without limitation statements to the effect that the Company or its management "will," "believes," "expects," "plans," "intends," "continue," "anticipates," is "positioned" or other similar expressions). These forward-looking statements ...

Financial Performance - Q2 2025 - Mettler Toledo's Q2 2025 sales increased by 4% to $983221000 compared to $946750000 in Q2 2024[24] - Local currency sales growth was 2% in Q2 2025[7, 12, 18, 24] - Adjusted EPS increased by 5% to $1009 in Q2 2025, compared to $965 in Q2 2024[7, 24] - Adjusted operating margin decreased by 120 basis points to 288% in Q2 2025[7, 24] Financial Performance - YTD 2025 - Year-to-date net sales decreased by 0% to $1866965000 compared to $1872699000 in YTD 2024[25] - Year-to-date local currency sales growth was 0%[15, 22, 25] - Adjusted EPS decreased by 1% to $1827 year-to-date[25] - Adjusted operating margin decreased by 150 basis points to 279% year-to-date[25] Sales by Geography - Q2 2025 - Americas sales increased to $414000000 with 3% local currency growth[12] - Europe sales decreased to $274000000 with 0% local currency growth[12] - Asia/ROW sales increased to $295000000 with 3% local currency growth[12] Sales by Product - Q2 2025 - Laboratory product sales increased to $538000000 with 1% local currency growth[18] - Industrial product sales increased to $395000000 with 4% local currency growth[18]

Q2 2025 Financial Performance - Average paid worksite employees increased by 1%[10] - Worksite employees paid from new client sales increased by 2% compared to Q2 2024[10] - Adjusted EBITDA decreased by 52%[14] - Adjusted EPS decreased by 70%[14] - Operating expenses decreased by 3% compared to Q2 2024[14] YTD June 2025 Financial Performance - Average paid worksite employees increased by 1%[17] - Worksite employees paid from new client sales increased by 2% compared to 2024[17] - Adjusted EBITDA decreased by 36%[20] - Adjusted EPS decreased by 42%[20] 2025 Outlook - The company expects average WSEEs paid to be between 310,300 and 313,400, representing a year-over-year increase of 1% to 2%[25] - The company expects adjusted EPS to be between $181 and $251, representing a year-over-year decrease of 49% to 30%[25] - The company expects adjusted EBITDA to be between $170 million and $205 million, representing a year-over-year decrease of 37% to 24%[25]